HOTH Key Statistics, Chart & Performance
The current stock price of HOTH is 1.03 USD. In the past month the price decreased by -10.92%. In the past year, price decreased by -44.21%.
HOTH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.09 | 999.74B | ||
| JNJ | JOHNSON & JOHNSON | 19.81 | 495.41B | ||
| MRK | MERCK & CO. INC. | 12.35 | 270.07B | ||
| PFE | PFIZER INC | 7.97 | 145.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.33 | 111.18B | ||
| ZTS | ZOETIS INC | 20.38 | 56.95B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.85 | 23.37B | ||
| VTRS | VIATRIS INC | 5.38 | 14.45B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.53 | 11.70B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.58B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.36B |
Related stock screener links
About HOTH
Company Profile
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
Company Info
HOTH THERAPEUTICS INC
1177 Avenue Of The Americas, 5Th Floor Suite 5066
New York City NEW YORK 10020 US
CEO: Robb Knie
Employees: 2
Phone: 16467562997
HOTH THERAPEUTICS INC / HOTH FAQ
What does HOTH do?
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
What is the stock price of HOTH THERAPEUTICS INC today?
The current stock price of HOTH is 1.03 USD. The price decreased by -2.83% in the last trading session.
What is the dividend status of HOTH THERAPEUTICS INC?
HOTH does not pay a dividend.
What is the ChartMill rating of HOTH THERAPEUTICS INC stock?
HOTH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of HOTH THERAPEUTICS INC (HOTH)?
HOTH THERAPEUTICS INC (HOTH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.06).
How many employees does HOTH THERAPEUTICS INC have?
HOTH THERAPEUTICS INC (HOTH) currently has 2 employees.
HOTH Technical Analysis
HOTH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HOTH. HOTH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
HOTH Financial Highlights
Over the last trailing twelve months HOTH reported a non-GAAP Earnings per Share(EPS) of -1.06. The EPS increased by 20.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -131.58% | ||
| ROE | -147.77% | ||
| Debt/Equity | 0 |
HOTH Forecast & Estimates
7 analysts have analysed HOTH and the average price target is 4.59 USD. This implies a price increase of 345.63% is expected in the next year compared to the current price of 1.03.